Overview
FTH market data
Price History
FTH price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$16.72 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.09 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.43 – $37.90 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $738.3M.
Company News
HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price TargetBenzinga · Aug 11, 2026, 12:17 PM
Faeth Therapeutics To Present Translational Data And Pharmacokinetic/Pharmacodynamic Analysis For PIKTOR, Oral Combination Of Serabelisib And Sapanisertib, At 2026 Summit For STOP CancerBenzinga · Aug 7, 2026, 11:35 AM
Faeth Therapeutics shares are trading lower after the company reported a wider net loss for the second quarter driven by a sharp increase in expenses.Benzinga · Aug 4, 2026, 2:22 PM
8-K filing — Faeth Therapeutics, Inc. (FTH)SEC EDGAR · Aug 4, 2026, 11:40 AM
Faeth Therapeutics Q2 EPS $(2.84) Beats $(3.29) EstimateBenzinga · Aug 4, 2026, 11:34 AM
This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · Jul 31, 2026, 1:11 PM
This Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For FridayBenzinga · Jul 31, 2026, 11:47 AM
Raymond James Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $56Benzinga · Jul 31, 2026, 10:14 AM
This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · Jul 28, 2026, 1:02 PM
Oppenheimer Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $60Benzinga · Jul 28, 2026, 9:26 AM